COFEPRIS Sets New Priorities for Health Regulatory System

COFEPRIS defined new priorities for Mexico's Federal Sanitary System, centered on technical harmonization, digitalization, backlog reduction, and risk-based sanitary surveillance, following a January 2026 General Health Law reform that formalized the system's federal-state structure. The announcement extends a broader regulatory modernization trend in Mexico that includes shorter clinical trial approval times and new medical device registration pathways. 

The Federal Commission for the Protection Against Sanitary Risks (COFEPRIS) defined new working priorities for Mexico's Federal Sanitary System (SFS) during a national meeting held Aug. 5–6, 2026, bringing together state sanitary risk protection authorities and state public health laboratories. COFEPRIS identified the harmonization of technical criteria, the digitalization of procedures, the reduction of regulatory backlogs, and the strengthening of risk-based sanitary surveillance as its core objectives for the system. The commission did not disclose implementation timelines, budgets, or the specific procedures affected by these initiatives.

Víctor Hugo Borja, Federal Commissioner, COFEPRIS, presented the transformation plan for 2026 during the meeting, outlining a shift toward a regulatory model built around risk management, product lifecycle monitoring, and the adoption of international standards. COFEPRIS also reported progress in simplifying administrative procedures, citing an average reduction in requirements and resolution times, though it did not specify how many requirements were eliminated or which procedures were affected. 

The meeting followed a legal change to Mexico's regulatory framework. A decree reforming the General Health Law, published in the Official Gazette of the Federation on Jan. 15, 2026, added Article 9 Bis, which formally defines the composition of the Federal Sanitary System. Under this provision, the system comprises COFEPRIS, the sanitary protection authorities of the states that have signed coordination agreements to exercise regulatory, control, surveillance, and promotion functions, and the state public health laboratories in their sanitary regulation capacity. The August meeting reviewed the 2026 Annual Work Program, updates to the Coordination of Powers Agreements, and monitoring of state sanitary risk protection areas, though COFEPRIS did not indicate whether all state-level agreements had been updated or provide a timeline for completion.

The reform builds on a broader modernization push that has defined COFEPRIS's agenda under Borja, who took office in January 2026. The agency has already launched a new framework for medical device registration that incorporates international recognition pathways and abbreviated review mechanisms for products previously approved by trusted foreign regulators. COFEPRIS has also moved to streamline clinical research oversight.   

COFEPRIS and the National Bioethics Commission briefed 435 representatives of Mexico's clinical research sector on a General Health Law reform in force since January 2026, which seeks to streamline protocol submission and review without lowering ethical or scientific requirements, following a separate cut in approval timelines. Industry observers have described these efforts to simplify administrative procedures and accelerate approval timelines as being closely watched by pharmaceutical, medical device, and healthcare technology companies seeking greater regulatory certainty in Mexico. 

One of the components presented during the meeting was the Sanitary Management Model for High-Risk Products and Services, supported by a set of Harmonization Master Guides. According to COFEPRIS, these instruments are designed to prioritize regulatory intervention on products and services considered higher risk. 

The agenda also covered progress on monitoring recreational water with primary contact, such as beaches, drinking water quality, and technovigilance. A separate track addressed the National Network of State Public Health Laboratories, where COFEPRIS presented follow-up on a situational diagnosis and a strategy to strengthen analytical capacities. 

Participation in the World Health Organization's (WHO) Global Benchmarking Tool (GBT) was also listed among the priority actions. The GBT is used by the WHO to assess national regulatory systems for medical products and identify maturity levels and areas for improvement. Its inclusion in the SFS agenda reflects an ongoing evaluation and strengthening process rather than a new rule directed at companies or establishments.

For manufacturers, importers, distributors, service providers, and other entities subject to sanitary control, the meeting did not introduce new requirements, obligations, deadlines, or procedures that take effect immediately. The practical scope of these changes will depend on how COFEPRIS develops indicators for backlog and resolution times, a digitalization schedule, risk classification criteria, the state of coordination agreements with each of the 32 states, and targets for strengthening state laboratories.